• Exploration of Targeted Anti-tumor Therapy

    eISSN: 2692-3114
    EiC: Nicola Normanno, MD, President of Italian Cancer Society (SIC)
    Frequency: Bimonthly
    APC: No Article Processing Charge before January 31, 2025
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: PubMed/PMC, Scopus
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Meta-Analysis
    Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis
    Aim: This article is based on our previous research, which was presented as a post at the Congress Aiom 2022 Congress and published in Tumori Journal as Conference Abstract (Tumori J. 2022;108:1 [...] Read more.
    Marco Filetti ... Gennaro Daniele
    Published: December 01, 2023 Explor Target Antitumor Ther. 2023;4:1136–1144
    DOI: https://doi.org/10.37349/etat.2023.00187
    View:27
    Download:5
    Times Cited: 0
    Open Access
    Commentary
    A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
    On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin [...] Read more.
    Dimitrios Bouzianas, Stella Bouziana
    Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1128–1135
    DOI: https://doi.org/10.37349/etat.2023.00186
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:328
    Download:12
    Times Cited: 0
    Open Access
    Perspective
    Cholesterol esterification and p53-mediated tumor suppression
    Many human cancers carry missense mutations in or deletions of the tumor protein 53 (TP53) tumor suppressor gene. TP53’s product, p53 regulates many biological processes, including cell metabolism [...] Read more.
    Youjun Li ... Edward V. Prochownik
    Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1122–1127
    DOI: https://doi.org/10.37349/etat.2023.00185
    This article belongs to the special issue Therapeutic Targeting of the Tumor Microenvironment
    View:259
    Download:13
    Times Cited: 0
    Open Access
    Original Article
    Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression
    Aim: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with a survival rate below fifty percent. Addressing meager therapeutic options, a series of small m [...] Read more.
    Levi Arnold ... Sufi Mary Thomas
    Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1104–1121
    DOI: https://doi.org/10.37349/etat.2023.00184
    This article belongs to the special issue Therapeutic Targeting of the Tumor Microenvironment
    View:336
    Download:19
    Times Cited: 0
    Open Access
    Systematic Review
    Impact of coronavirus disease 2019 pandemic on good clinical practice trials in oncology
    Aim: Coronavirus disease 2019 (COVID-19) became pandemic on 11th March 2020 and it deeply stressed the healthcare system. Cancer patients represent a vulnerable population, so many recommendation [...] Read more.
    Veronica Agostinelli ... Rossana Berardi
    Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1095–1103
    DOI: https://doi.org/10.37349/etat.2023.00183
    This article belongs to the special issue COVID-19 and Cancer
    View:210
    Download:5
    Times Cited: 0
    Open Access
    Review
    Coronavirus disease 2019 and lung cancer: where are we?
    Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antine [...] Read more.
    Abrahams Ocanto ... Felipe Couñago
    Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1082–1094
    DOI: https://doi.org/10.37349/etat.2023.00182
    This article belongs to the special issue COVID-19 and Cancer
    View:260
    Download:6
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:19968
    Download:2721
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:12823
    Download:639
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6377
    Download:263
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of [...] Read more.
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26–52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:5602
    Download:176
    Times Cited: 0
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4646
    Download:261
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t [...] Read more.
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:3–25
    DOI: https://doi.org/10.37349/etat.2020.00002
    View:4637
    Download:115
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:19968
    Download:2721
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
    DOI: https://doi.org/10.37349/etat.2022.00114
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:1845
    Download:901
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:12823
    Download:639
    Open Access
    Perspective
    Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
    Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However,  [...] Read more.
    Ai Tsuji ... Satoru Matsuda
    Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:460–473
    DOI: https://doi.org/10.37349/etat.2023.00145
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:916
    Download:392
    Times Cited: 0
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4218
    Download:323
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6377
    Download:263
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:19968
    Download:2721
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:12823
    Download:639
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4218
    Download:323
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:3295
    Download:198
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6377
    Download:263
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4646
    Download:261
    Special Issues